Trials / Completed
CompletedNCT00977262
Postprandial Inflammation and Fatty Acids
Effects of Fatty Acids on Postprandial Inflammatory Response of Healthy Obese and Type 2 Diabetic Obese Subjects
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Wageningen University · Academic / Other
- Sex
- Male
- Age
- 50 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The main objective is to elucidate the acute effects of an oral intake of either saturated, monounsaturated or polyunsaturated fatty acids on peripheral blood mononuclear cells (PBMC) whole genome expression of obese and type 2 diabetic obese subjects.
Detailed description
Consumption of high-fat diets can lead to postprandial dyslipidemia, impairment of endothelial function, activation of immune cells and changes in gene expression profiles of immune cells such as peripheral blood mononuclear cells (PBMC). Recently it was shown that postprandial gene expression profiles of PBMC and plasma triglyceride (TG) and free fatty acid (FFA) responses are dependent on the type of dietary fat consumed (i.e. saturated, monounsaturated and polyunsaturated). Since obese and diabetic subjects usually are in a pro-inflammatory state and have dyslipidemia and endothelial dysfunction we are interested in the effect of different fatty acids in a high load on the PBMC gene expression profiles, plasma cytokine profiles and endothelial function of these subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | High saturated fat shake | milkshake containing 95 gram of fat, high percentage of saturated fat |
| OTHER | High monounsaturated fat shake | milkshake containing 95 gram of fat, high percentage of monounsaturated fat |
| OTHER | High polyunsaturated fat shake | milkshake containing 95 gram of fat, high percentage polyunsaturated fat |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2009-09-15
- Last updated
- 2010-04-21
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00977262. Inclusion in this directory is not an endorsement.